Skip to content

Application study of different concentrations of bupivacaine liposomes combined with proximal adductor canal and anserine tendon block in anterior cruciate ligament reconstruction under knee arthroscopy

Application study of different concentrations of bupivacaine liposomes combined with proximal adductor canal and anserine tendon block in anterior cruciate ligament reconstruction under knee arthroscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119978
Enrollment
Unknown
Registered
2026-03-06
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ruptured anterior cruciate ligament

Interventions

Group N1:Preoperatively, 15 ml of 0.333% bupivacaine liposome was used for proximal adductor canal block + pes anserinus block.
Group N2:Preoperatively, 15 ml of 0.443% bupivacaine liposome was used for proximal adductor canal block + pes anserinus block.
Group N3:Preoperatively, 15 ml of 0.665% bupivacaine liposome was used for proximal adductor canal block + pes anserinus block.
Group C:Only general anesthesia is accepted, without combined ultrasound-guided nerve block

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18-60, any gender; 2. ASA classification I-II; 3. Patients undergoing unilateral anterior cruciate ligament arthroscopic surgery; 4. Able to complete the questionnaire independently or with the assistance of family members; 5. All patients and their family members have signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Incomplete documentation, 2. Infection at the puncture site, 3. Preoperative neurological dysfunction or central nervous system disease, 4. Severe psychological issues, history of psychiatric disorders, 5. Severe cardiopulmonary disease or abnormal liver and kidney function, 6. Abnormal blood coagulation, 7. History of chronic pain, drug dependency, 8. Allergy to any component of analgesics, 9. Use of other analgesics within 24 hours, and change to other anesthesia methods.

Design outcomes

Primary

MeasureTime frame
Pain score;The time of the first postoperative ambulation;Quadriceps muscle strength;

Secondary

MeasureTime frame
Ramsay calm score;Was there any sudden pain 3 days after the operation;The situation of additional painkillers administered in the ward 3 days after the surgery;Increase the dosage of tramadol and flurbiprofen axetil in the resuscitation room;The occurrence of postoperative adverse reactions (such as restlessness, dizziness, nausea, vomiting, etc.);

Countries

China

Contacts

Public ContactGuangying Zhang

The First Affiliated Hospital of Guangxi Medical University

1244418665@qq.com+86 182 6918 5980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026